Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH, van Erpecum KJ, Schalm SW, Zaaijer HL, Brouwer JT, Gelderblom HC, de Knegt RJ, Minke Bakker C, Reesink HW, Janssen HL; Netherlands Association of Gastroenterologists and Hepatologists. Buster EH, et al. Among authors: reesink hw. Neth J Med. 2008 Jul-Aug;66(7):292-306. Neth J Med. 2008. PMID: 18663260 Free article. Review.
Treatment of chronic hepatitis C virus infection - Dutch national guidelines.
de Bruijne J, Buster EH, Gelderblom HC, Brouwer JT, de Knegt RJ, van Erpecum KJ, Schalm SW, Bakker CM, Zaaijer HL, Janssen HL, Reesink HW; Netherlands Association of Gastroenterologists and Hepatologists. de Bruijne J, et al. Among authors: reesink hw. Neth J Med. 2008 Jul-Aug;66(7):311-22. Neth J Med. 2008. PMID: 18663263 Free article. Review.
Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor.
de Bruijne J, Bergmann JF, Weegink CJ, van Nieuwkerk CM, de Knegt RJ, Komoda Y, van de Wetering de Rooij JJ, van Vliet A, Jansen PL, Molenkamp R, Schinkel J, Reesink H, Janssen HL. de Bruijne J, et al. Antivir Ther. 2010;15(5):765-73. doi: 10.3851/IMP1606. Antivir Ther. 2010. PMID: 20710058 Clinical Trial.
Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design.
Hotho DM, de Bruijne J, O'Farrell AM, Boyea T, Li J, Bracken M, Li X, Campbell D, Guler HP, Weegink CJ, Schinkel J, Molenkamp R, van de Wetering de Rooij J, van Vliet A, Janssen HL, de Knegt RJ, Reesink HW. Hotho DM, et al. Among authors: reesink hw. Antivir Ther. 2012;17(2):365-75. doi: 10.3851/IMP1989. Epub 2011 Nov 30. Antivir Ther. 2012. PMID: 22293533 Clinical Trial.
[New class of medicines for chronic hepatitis C].
Aronson SJ, de Bruijne J, Schinkel J, Weegink CJ, van der Valk M, Reesink HW. Aronson SJ, et al. Among authors: reesink hw. Ned Tijdschr Geneeskd. 2012;156(10):A3840. Ned Tijdschr Geneeskd. 2012. PMID: 22394440 Review. Dutch.
Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.
van der Ree MH, de Vree JM, Stelma F, Willemse S, van der Valk M, Rietdijk S, Molenkamp R, Schinkel J, van Nuenen AC, Beuers U, Hadi S, Harbers M, van der Veer E, Liu K, Grundy J, Patick AK, Pavlicek A, Blem J, Huang M, Grint P, Neben S, Gibson NW, Kootstra NA, Reesink HW. van der Ree MH, et al. Among authors: reesink hw. Lancet. 2017 Feb 18;389(10070):709-717. doi: 10.1016/S0140-6736(16)31715-9. Epub 2017 Jan 11. Lancet. 2017. PMID: 28087069 Clinical Trial.
353 results